Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Related Citations for PubMed (Select 23730418)


Expression of DBC1 and Androgen Receptor Predict Poor Prognosis in Diffuse Large B Cell Lymphoma.

Park HS, Bae JS, Noh SJ, Kim KM, Lee H, Moon WS, Chung MJ, Kang MJ, Lee DG, Jang KY.

Transl Oncol. 2013 Jun 1;6(3):370-81. Print 2013 Jun.


Acetylation status of P53 and the expression of DBC1, SIRT1, and androgen receptor are associated with survival in clear cell renal cell carcinoma patients.

Noh SJ, Kang MJ, Kim KM, Bae JS, Park HS, Moon WS, Chung MJ, Lee H, Lee DG, Jang KY.

Pathology. 2013 Oct;45(6):574-80. doi: 10.1097/PAT.0b013e3283652c7a.


SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.

Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, Kwak JY, Park BH, Park HS, Chung MJ, Kang MJ, Lee DG, Kim HS, Shim H, Moon WS.

Am J Surg Pathol. 2008 Oct;32(10):1523-31. doi: 10.1097/PAS.0b013e31816b6478.


High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.

Li ZM, Huang JJ, Xia Y, Zhu YJ, Zhao W, Wei WX, Jiang WQ, Lin TY, Huang HQ, Guan ZZ.

Eur J Haematol. 2012 Jun;88(6):510-7. doi: 10.1111/j.1600-0609.2012.01778.x. Epub 2012 Mar 27.


Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma.

Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS, Lee H, Chung MJ, Kang MJ, Lee DG, Moon WS, Jang KY.

Clin Cancer Res. 2009 Jul 1;15(13):4453-9. doi: 10.1158/1078-0432.CCR-08-3329. Epub 2009 Jun 9.


Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma.

Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH, Jung SH, Youn HJ, Lee BK, Chung MJ, Koh DH, Moon WS, Jang KY.

Hum Pathol. 2011 Feb;42(2):204-13. doi: 10.1016/j.humpath.2010.05.023. Epub 2010 Nov 5.


BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.

Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, Chan WC.

Clin Cancer Res. 2011 Dec 15;17(24):7785-95. doi: 10.1158/1078-0432.CCR-11-0267. Epub 2011 Sep 20.


Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas.

De Paepe P, Achten R, Verhoef G, Wlodarska I, Stul M, Vanhentenrijk V, Praet M, De Wolf-Peeters C.

J Clin Oncol. 2005 Oct 1;23(28):7060-8. Epub 2005 Aug 29.


Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.

van Imhoff GW, Boerma EJ, van der Holt B, Schuuring E, Verdonck LF, Kluin-Nelemans HC, Kluin PM.

J Clin Oncol. 2006 Sep 1;24(25):4135-42.


[Expression of microRNA-223 and its clinicopathologic correlation in diffuse large B-cell lymphoma].

Yao XX, Wang JF, Wang YH, Gao N.

Zhonghua Bing Li Xue Za Zhi. 2012 Jun;41(6):366-70. doi: 10.3760/cma.j.issn.0529-5807.2012.06.002. Chinese.


[Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].

Yao WK, Wang YP, Peng F, Zheng Y, Zou YB, Gao JN, Liu XL.

Zhonghua Bing Li Xue Za Zhi. 2012 Dec;41(12):818-22. doi: 10.3760/cma.j.issn.0529-5807.2012.12.006. Chinese.


High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma.

Wu ZL, Song YQ, Shi YF, Zhu J.

J Hematol Oncol. 2011 Aug 1;4(1):31. doi: 10.1186/1756-8722-4-31.


Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes.

Saad AA, Awed NM, Abdel-Hafeez ZM, Kamal GM, Elsallaly HM, Alloub AI.

Saudi Med J. 2010 Feb;31(2):135-41.


Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.

Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.

J Clin Oncol. 2008 Oct 1;26(28):4587-94. doi: 10.1200/JCO.2007.15.9277. Epub 2008 Jul 28.


Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC.

Blood. 2004 Jan 1;103(1):275-82. Epub 2003 Sep 22.


The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.

Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, Rosenwald A, Jack A, Sundstrom C, Cogliatti S, Trougouboff P, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Gisselbrecht C.

J Clin Oncol. 2011 Nov 1;29(31):4079-87. doi: 10.1200/JCO.2011.35.4423. Epub 2011 Sep 26.


MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.

Yoon SO, Jeon YK, Paik JH, Kim WY, Kim YA, Kim JE, Kim CW.

Histopathology. 2008 Aug;53(2):205-17. doi: 10.1111/j.1365-2559.2008.03076.x.


CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis.

Ohshima K, Kawasaki C, Muta H, Muta K, Deyev V, Haraoka S, Suzumiya J, Podack ER, Kikuchi M.

Histopathology. 2001 Aug;39(2):156-62.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk